Obesity Drug Market to Remain Heavily Concentrated Among Two Firms, Hefty US Price Tags Dominate Sales
![](https://www.mcalindenresearchpartners.com/wp-content/uploads/2024/02/samuel-ramos-mz9koyBQd4Q-unsplash-1024x683.jpg)
Popular GLP-1 agonists from Novo Nordisk and Eli Lilly are projected to retain a combined 80% market share among weight…
McAlinden Research PartnersFebruary 20, 2024